The latest published report by Polaris Market Research. The report “Lewy Body Dementia Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Modafinil, Cholinesterase Inhibitors, Benzodiazepine, Antipsychotic Drugs, Anti-depressants, and Carbidopa-Levodopa); By Indication [Parkinson’s Disease and Dementia with Lewy Bodies (DLB)]; By Distribution Channel; By Regions Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The global Lewy body dementia treatment market was valued at USD 3,597.93 million in 2019 and size is predicted to reach USD 5.31 billion by 2027, growing at a CAGR of 5.08% during 2020-2027. Lewy body dementia is a progressive disorder associated with dysfunction of the central nervous system and characterized by deposits of alpha-synuclein, a protein in the brain. The unusual deposits in the brain formed Lewy bodies, which can lead to several problems with body movement, thinking, mood, and behavior. Lewy body dementia is the most common disease after Alzheimer’s which is rapidly growing and subsequently foster global market growth. Recent developments include the new launches and clinical studies such as LY3154207, ABBV-0805, etc. The launches of drugs are associated with the diagnosis of dementia with Lewy body, Parkinson’s, and Alzheimer’s diseases which further leads to drive the growth of the global market.
Request for a sample Report: https://www.polarismarketresearch.com/industry-analysis/lewy-body-dementia-treatment-market/request-for-sample
Market participants such as Mallinckrodt Pharmaceuticals, BioArctic AB, Bausch Health Companies Inc., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Allergan Plc., Noven Pharmaceuticals, Inc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, Eisai Co., Ltd., Novartis AG, GlaxoSmithKline, Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Sanofi AG, and Mylan NV are some of the key players operating in the industry.
Players in the industry are focusing on developing new methods and drugs for LBD, new launches, increasing expansions, collaborations, and partnerships to enhance their market and revenue share. For instance, in August 2020, Proteostasis Therapeutics, Inc. and Yumanity Therapeutics entered into a definitive merger agreement, and after combining they operate under the name Yumanity Therapeutics, Inc. The merger leads to enhance Yumanity’s pipeline of innovative, disease-modifying methods and solutions for neurological disorders.
The prominent factors favoring the global market growth include the rising initiatives by the legal and regulatory authorities to develop an effective and safe treatment for the LBD disorder in the patients. For instance, in October 2019, an LBD Association Research Center of Excellence, Georgetown University Medical Center, has taken the initiative to offer 3 clinical trials to devise new methods and treatments for Lewy body dementia and Alzheimer’s disease.
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/lewy-body-dementia-treatment-market/request-for-discount-pricing
Rising incidences of getting affected by Alzheimer’s disease and related disorders include vascular dementia, Lewy body dementia, frontotemporal degeneration, and Parkinson’s disease has witnessed the surge in demand for the treatment of the patients. The regulatory authorities and researchers are engaged in discovering new methods and solutions to provide effective treatment of the disorder.
For instance, in June 2020, The Harry T. Mangurian, Jr. Foundation and Florida Atlantic University’s Schmidt College of Medicine have amalgamated its forces to discover and research medicine to prevent dementia. The grant of USD 3 million will allow FAU’s Schmidt College of Medicine to establish a new FAU Center for Brain Health. Furthermore, in July 2020, the Journal of the American Medical Association (JAMA) has published that researchers have formed a new p-tau217 blood test, which is proved to hold remarkable results in the diagnosis of Alzheimer’s disease and related disorders in the patients.
Table of Contents
Lewy Body Dementia Treatment Market Insights
Lewy Body Dementia Treatment Market Assessment by Drug Type
- Cholinesterase Inhibitors
- Antipsychotic Drugs
Lewy Body Dementia Treatment Market Assessment by Indication
- Parkinson’s Disease
- Dementia with Lewy Bodies (DLB)
Lewy Body Dementia Treatment Market Assessment by Distribution Channel
- Drug Stores
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
Lewy Body Dementia Treatment Market Assessment by Geography
- North America
- Asia Pacific
- South Korea
- Central & South America
- Middle East & Africa
- Saudi Arabia
- South Africa
Find more research reports on Healthcare Industry by PMR,
Have Any Query Or Specific Requirement? Feel Free To Ask Our Industry Experts At : https://www.polarismarketresearch.com/industry-analysis/lewy-body-dementia-treatment-market/speak-to-analyst
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Polaris Market Research